Sordarins: In vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2863-2869

  Herreros, E ^a   Martinez, C M ^a   Almela, M J ^a   Marriott, M S ^b   Gomez De Las Heras, F ^a   Gargallo Viola, D ^a  

^a GLAXOSMITHKLINE   (Spain)

^b GSK   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE; GM 193663; GM 211676; GM 222712; GM 237354; PENTAMIDINE; PROTEIN SYNTHESIS INHIBITOR; SORDARIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; ARTICLE; ASPERGILLOSIS; CANDIDA; DERMATOPHYTE; DRUG SENSITIVITY; FUNGICIDAL ACTIVITY; IMMUNE DEFICIENCY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMOCYSTIS CARINII; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION;

EID: 0031724740     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2863     Document Type: Article

References (38)

1. Anaissie, E. J. 1992. Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review. Clin. Infect. Dis. 14(Suppl. 1): 43-53.
2. Colthurst, D. R., P. Chalk, M. Hayes, and M. F. Tuite. 1991. Efficient translation of synthetic and natural mRNAs in an mRNA-dependent cell free system from the dimorphic fungus Candida albicans. J. Gen. Microbiol. 137:851-857.
3. Coval, S. J., M. S. Puar, D. W. Phife, J. S. Terracciano, and M. Patel. 1995. SCH57404, an antifungal agent possessing the rare sordaricin skeleton and tricyclin moiety. J. Antibiot. 48:1171-1172.
4. Dei-Cas, E., E. M. Aliouat, C. Mullet, E. Mazars, and D. Gargallo. 1997. A new antimicrobial molecule (GM 237354) highly active against Pneumocystis carinii: in vivo studies and ultrastructural data, abstr. F-65, p. 157. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Domínguez, J. M., V. A. Kelly, O. S. Kinsman, M. S. Marriott, F. Gómez de las Heras, and J. J. Martín. 1998. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob. Agents Chemother. 42:2274-2278.
6. Domínguez, J. M., and J. J. Martín. 1998. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob. Agents Chemother. 42:2279-2283.
7. Espinel-Ingroff, A., M. Bartlett, R. Bowden, N. X. Chin, C. Cooper, Jr., A. Fothergill, M. R. McGinnis, P. Menezes, S. A. Messer, P. W. Nelson, F. C. Odds, L. Pasarell, J. Peter, M. A. Pfaller, J. H. Rex, M. G. Rinaldi. G. S. Shankland, T. J. Walsh, and I. Weitzman. 1997. Multicenter evaluation of proposed standardized procedure for antitungal susceptibility testing of filamentous fungi. J. Clin. Microbiol. 35:139-143.
8. Georgopapadakou, N. H., and T. J. Walsh. 1996. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob. Agents Chemother. 40:279-291.
9. Georgopapadakou, N. H., and T. J. Walsh. 1994. Human mycoses: drugs and targets for emerging pathogens. Science 264:371-373.
10. Gold, W., H. A. Stout, J. F. Pagano, and R. Donovick. 1955-1956. Amphotericins A and B, antifungal antibiotics produced by a streptomycete. I. In vitro studies. Antibiot. Ann. 1955/1956:579-586.
11. Groll, A. H., P. M. Shah, C. Mentzel, M. Schneider, G. Just-Nuebling, and K. Huebner. 1996. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33:23-32.
12. Hall, C. C., A. B. Bertasso, J. D. Watkins, and N. H. Georgopapadakou. 1992. Screening assays for protein synthesis inhibitors. J. Antibiot. 45:1697-1699.
13. Hauser, D., and H. P. Sigg. 1971. Isolieting und abbau von Sordarin. Helv. Chim. Acta 54:1178-1190.
14. Herreros, E., M. J. Almela, M. Martinez, S. Lozano, H. Jackson, E. M. Aliouat, and D. Gargallo-Viola. 1997. Microplate assays for in vitro evaluation of anti-Pneumocystis drugs. J. Eukaryot. Microbiol. 44:43S-44S.
15. Herreros, E., A. Martinez, E. Jimenez, P. Aviles, M. J. Almela, S. Lozano, C. M. Martinez, R. San Roman, E. M. Aliouat, A. Alvarez, F. Gomez de las Heras, and D. Gargallo. 1997. Anti-Pneumocystosis activity of GM 237354 in vitro and in vivo, abstr. F-64, p. 156. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
16. Herreros, E., C. M. Martinez, M. J. Almela, S. Lozano, F. Gomez de las Heras, and D. Gargallo. 1997. In vitro activity of GM 237354 against a broad range of fungi, abstr. F-57, p. 155. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Hughes, W. T. 1991. Pneumocystis carinii pneumonia: new approaches to diagnosis, treatment and prevention. Pediatr. Infect. Dis. J. 10:391-399.
18. Jahn, B., E. Martin, A. Stueben, and S. Bhakdi. 1995. Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay. J. Clin. Microbiol. 33:661-667.
19. Kamath, A., and K. Chakraburtty. 1989. Role of yeast elongation factor 3 in the elongation cycle. J. Biol. Chem. 264:15423-15428.
20. Kinsman, O. S., P. A. Chalk, H. C. Jackson, R. F. Middleton, A. Shuttleworth, B. A. M. Rudd, C. A. Jones, H. M. Noble, H. G. Wildman, M. J. Dawson, S. Lynn, and M. V. Hayes. 1998. Isolation and characterisation of an antifungal antibiotic (GR 135402) with protein synthesis inhibition. J. Antibiot. 51:41-49.
21. Martinez-Suarez, J. V. and J. L. Rodriguez-Tudela. 1995. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob. Agents Chemother. 39:1512-1516.
22. Members of the European Concerted Action on Pneumocystis carinii. 1996. In vitro systems in Pneumocystis research. Parasitol. Today 12:245-249.
23. Meyer, R. D., L. S. Yong, D. Armstrong, and B. Yu. 1973. Aspergillosis complicating neoplasic disease. Am. J. Med. 56:6-15.
24. National Committee for Clinical Laboratory Standards. 1993. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd ed., vol. 10, no. 8. Approved standard M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
25. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard. Document M27-A. National Committee for Clinical Laboratory Standards, Villanova, Pa.
26. O'Donell, M. R., G. M. Schmitt, B. R. Tegtmeier, C. Faucett, J. L. Fahey, J. Ito, A. Nadamanec, J. Niland, P. Parker, E. P. Smith, D. S. Snyder, A. S. Stein, K. G. Blume, and S. J. Forman. 1994. Prediction of systemic fungal infection in allogenic marrow transplant recipients: impact of amphotericin B prophylaxis in high-risk patients. J. Clin. Oncol. 12:827-834.
27. Ogita, T., A. Hayashi, S. Sato, and W. Furutani. February 1987. Japanese patent 62-40292.
28. Okada, Y., M. Nagabato, and M. Kamitami. 1994. Antifungal agent BE-31405. Japanese patent 157,582.
29. Pannuti, C. S., R. Gingrich, M. A. Pfaller, C. Kao, and R. P. Wenzel. 1992. Nosocomial pneumonia in patients having bone marrow transplant. Cancer 69:2653-2662.
30. Pfaller, M. A., and R. Wenzel. 1992. The impact of changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 11:287-291.
31. Richardson, M. D. 1991. Opportunistic and pathogenic fungi. J. Antimicrob. Chemother. 28(Suppl. A):1-11.
32. Rodriguez-Tudela, J. L., and J. V. Martinez-Suarez. 1994. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob. Agents Chemother. 38:45-48.
33. Sigg, H. P., and C. Stoll. August 1969. U.K. patent 1,162,027.
34. Skogerson, L., and D. Engelhardt. 1977. Dissimilarity in chain elongation factor requirements between yeast and rat liver ribosomes. J. Biol. Chem. 252:1471-1475.
35. Stevens, D. A. 1997. Screening of sordaricin derivatives against endemic fungal pathogens, abstr. F-58, p. 155. In Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Walsh, T. J. 1992. Invasive fungal infections: problems and challenges in developing new antifungal compounds, p. 349-373. In J. Sutcliffe and N. H. Georgopapadakou (ed.), Emerging targets in antibacterial and antifungal chemotherapy. Chapman and Hall, New York, N.Y.
37. Walsh, T. J., and P. A. Pizzo. 1988. Nosocomial fungal infections. Annu. Rev. Microbiol. 42:517-545.
38. Yoshida, T., K. Uchida, and H. Yamaguchi. 1997. An ATP bioluminescence assay applicable to rapid fluconazole susceptibility testing of dermatophytes. Microbiol. Immunol. 41:377-386.